Arca
Skip to content
Tools
Tools

Bladder cancer

Drug research and approvals for bladder cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 413 studies of bladder cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 413
  • Trials authorized in Canada: 57
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting now

Newest posted first, of 413 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,410 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 278 whose ending is known, 26% met their primary endpoint, 8% missed it and 66% stopped early.

  • Completed, result not reported46633%
  • Ongoing45332%
  • Status unknown21315%
  • Stopped: other or unclear826%
  • Met its primary endpoint735%
  • Stopped: enrollment or feasibility604%
  • Missed its primary endpoint222%
  • Stopped: sponsor or business decision201%
  • Stopped: lack of efficacy101%
  • Stopped: funding6<1%
  • Stopped: safety5<1%

Trials authorized in Canada

The 10 newest of 57; search them all in Canada trials
Oct 30, 2026A phase 3 study evaluating sacituzumab tirumotecan plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) as induction therapy, followed by…MK-2870 / Keytruda sc (MK-3475A)Merck & Co. (MSD)Pending
Jul 22, 2026Active surveillance versus definitive local therapy for patients showing clinical complete response following neoadjuvant therapy for muscle-invasive bladder…Enfortumab vedotin (PADCEV) / Pembrolizumab (keytruda) / Gemcitabine /…Dr Marie-Pier St-LaurentOngoing
Jul 21, 2026A phase 3, open-label, randomized study to evaluate enfortumab vedotin in combination with pembrolizumab in adult participants with muscle-invasive bladder…Padcev / KeytrudaPfizerOngoing
May 1, 2026A phase 3, randomized study to evaluate the efficacy and safety of intravesical TARA-002 compared with investigator’s choice of intravesical chemotherapy in…TARA-002Protara Therapeutics, IncPending
Nov 24, 2025Nrg-GU015: the phase III adaptive radiation and chemotherapy for muscle invasive bladder cancer trial (ARCHER)MitomycinNrg Oncology At The American College of RadiologyOngoing
Nov 20, 2025A study of intravesical bacillus calmette-guerin (BCG) in combination with ALT-803 (N-803) in patients with non-muscle invasive bladder cancerN-803 (ALT-803, nai)ImmunityBioPending
Nov 10, 2025A phase II prospective single-arm study of dutasteride in patients with low-grade non-muscle invasive bladder cancerDutasterideChu De Québec-Université LavalPending
May 2, 2025A phase 2, multi-arm, multi-cohort, open-label study to evaluate the safety and efficacy of cretostimogene grenadenorepvec in participants with high-risk…Cretostimogene grenadenorepvec, ddmCG OncologyOngoing
Apr 16, 2025Randomized phase II trial of pembrolizumab and radiation vs. radiation and concurrent chemotherapy for high-grade T1 bladder cancer (parrc trial)Keytruda (pembrolizumab)Nrg OncologyPending
Mar 6, 2025A phase 2 open-label randomized study of V940 in combination with bcg versus bcg monotherapy in participants with high-risk non-muscle invasive bladder cancer…V940 (MRNA-4157) / Oncotice (bacillus calmette-guérin (BCG) strain tice)Merck & Co. (MSD)Ongoing

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jul 31, 2007Sodium ascorbate and menadione sodium bisulfiteTreatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)IC-MedTech CorporationDesignated

Medicines authorised in the EU

Newest first
May 28, 2026AdstiladrinNadofaragene firadenovecFerring Pharmaceuticals A/SEMA ↗
Feb 16, 2026AnktivaNogapendekin alfa inbakiceptImmunitybio Ireland LimitedEMA ↗
Apr 13, 2022PadcevEnfortumab vedotinAstellas Pharma Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.